References of "Osteoporosis International"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPrevalence of frailty in nursing home residents according to various diagnostic tools
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; Dardenne, Nadia ULg et al

in Osteoporosis International (2015), 26(S1), 160-161

Detailed reference viewed: 58 (14 ULg)
Full Text
Peer Reviewed
See detailBaseline characteristics of the Liège hand osteoarthritis cohort (LIHOC)
Neuprez, Audrey ULg; Bruyère, Olivier ULg; Dardenne, Nadia ULg et al

in Osteoporosis International (2015), 26(S1), 167

Detailed reference viewed: 20 (10 ULg)
Full Text
Peer Reviewed
See detailThe position of Strontium ranelate in today's management of osteoporosis
Reginster, Jean-Yves ULg; Brandi, M.L; Cannata-Andia, J. et al

in Osteoporosis International (2015), 26

Osteoporosis accounts for about 3 % of total European health-care spending. The low proportion of costs for the pharmacological prevention of osteoporotic fracture means that it is highly cost saving ... [more ▼]

Osteoporosis accounts for about 3 % of total European health-care spending. The low proportion of costs for the pharmacological prevention of osteoporotic fracture means that it is highly cost saving, especially in patient with severe osteoporosis or patients who cannot take certain osteoporosis medications due to issues of contraindications or tolerability. Following recent regulatory changes, strontium ranelate is now indicated in patients with severe osteoporosis for whom treatment with other osteoporosis treatments is not possible, and without contraindications including uncontrolled hypertension, established, current or past history of ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease. We review here today’s evidence for the safety and efficacy of strontium ranelate. The efficacy of strontium ranelate in patients complying with the new prescribing information (i.e. severe osteoporosis without contraindications) has been explored in a multivariate analysis of clinical trial data, which concluded that the antifracture efficacy of strontiumranelate is maintained in patients with severe osteoporosis without contraindications and also demonstrated how the new target population mitigates risk. Strontium ranelate is therefore an important alternative in today’s management of osteoporosis, with a positive benefit-risk balance, provided that the revised indication and contraindications are followed and cardiovascular risk is monitored. The bone community should be reassured that there remain viable alternatives in patients in whom treatment with other agents is not possible and protection against the debilitating effects of fracture is still feasible in patients with severe osteoporosis. [less ▲]

Detailed reference viewed: 86 (9 ULg)
Full Text
Peer Reviewed
See detailIs there a specific pattern of lean/fat mass ratio in sarcopenic subjects?
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Croisier, Jean-Louis ULg et al

in Osteoporosis International (2015), 26(S1), 145-146

Detailed reference viewed: 33 (6 ULg)
Full Text
Peer Reviewed
See detailA phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods
Bruyère, Olivier ULg; DEROISY, Rita ULg; Dardenne, Nadia ULg et al

in Osteoporosis International (2015)

Summary In a randomized, cross-over study, once monthly administration of vitamin D3 was preferred over a once daily administration of a fixed-dose combination of vitamin D3 and calcium, with a better ... [more ▼]

Summary In a randomized, cross-over study, once monthly administration of vitamin D3 was preferred over a once daily administration of a fixed-dose combination of vitamin D3 and calcium, with a better compliance but without any significant difference in the increase in vitamin D levels. Introduction The aim of the present study was to compare a once-monthly administration of vitamin D3 to a daily administration of a fixed-dose combination of vitamin D3 and calcium during two treatment periods of 6 months. Methods One hundred volunteers aged 50 years old or older were randomized to receive either one drinkable ampoule containing 25,000 IU vitamin D3 (D-Cure®, SMB) once monthly (group VD) or one chewable tablet containing 1000 mg calcium carbonate+800 IU vitamin D3 (Steovit Forte®, Takeda) once daily (group VDCa) during 6 months. After the first 6 months of treatment, the groups were reversed according to the randomized cross-over design. Treatment compliance (i.e. the primary outcome), preference, acceptability and vitamin D levels and adverse events were all collected. Results For the two periods, the patients had a significantly higher compliance in the VD group than in the VDCa group (p<0.0001). During the study, 50 (56.8 %) patients preferred the VD treatment, 16 (18.2 %) patients preferred the VDCa, and for 22 (25.0 %) patients, neither treatment was preferred. At the end of the first 6 months of treatment, the mean (SD) increase of 25(OH)D was 6.57 ng/mL (8.19) in the VD group and 3.88 ng/mL (10.0) in the VDCa group (p=0.16 between groups). Conclusion In this study, a once-monthly administration of vitamin D3 was preferred over a once-daily administration of a fixed-dose combination of vitamin D3 and calcium, with a better compliance but without any significant difference in the increase in vitamin D levels. [less ▲]

Detailed reference viewed: 55 (18 ULg)
Full Text
Peer Reviewed
See detailHow can we help implementing ESCEO algorithm in real life?
Reginster, Jean-Yves ULg

in Osteoporosis International (2015), 26(S1), 382

Detailed reference viewed: 18 (7 ULg)
Full Text
Peer Reviewed
See detailVitamin D status of schoolchildren in Northern Algeria, seasonal variations and determinants of vitamin D deficiency
Djennane, M; Lebbah, S; Roux, C et al

in Osteoporosis International (2014), 25(5), 1493-502

Summary There are no published data on the vitamin D status of children living in North Africa. In 435 healthy Algerian children 5–15 years old, we found that vitamin D insufficiency (serum 25 ... [more ▼]

Summary There are no published data on the vitamin D status of children living in North Africa. In 435 healthy Algerian children 5–15 years old, we found that vitamin D insufficiency (serum 25-hydroxyvitamin D (25OHD) <50 nmol/L) was frequent, especially in winter. Low vitamin D status was associated with increased parathyroid hormone (PTH) and leg deformation Introduction As there are no published data on the vitamin D status of children living in North Africa, we evaluated the 25OHD concentration of healthy Algerian children at the end of summer and at the end of winter. As secondary objectives, we studied the various determinants of vitamin D status and the PTH-25OHD relationship in these subjects. Methods Four hundred thirty-five children 5–15 years old were examined and had a blood sample in September 2010. Of them, 408 were sampled again in March 2011. Results Median 25OHD concentration in the whole group was 71.4 nmol/L in September and 52.9 nmol/L in March. In September, 58.4, 29.9, and 8.1 % had a 25OHD concentration below 75, 50, and 30 nmol/L respectively. In March, these percentages increased to 65.2, 41.4, and 17.4 % for the 75, 50, and 30 nmol/L threshold, respectively. In multivariate analysis, older age, darker skin phototype, low daily vitamin D and calcium intake, poor socioeconomic status, and short daily sun exposure remained significantly associated with a 25OHD <50 nmol/L at both visits. In 72 (16.6 %) children, genu varum/valgum was present. Compared to the 363 children without leg deformation, they presented more frequently with the risk factors of vitamin D insufficiency. They also had lower 25OHD concentrations and higher PTH and tALP. Serum PTH and 25OHD concentrations were negatively and significantly correlated (r=−0.43; p<0.001) without a 25OHD threshold above which PTH does not decrease anymore. Conclusion Despite a sunny environment, vitamin D insufficiency is frequent in healthy Algerian children. [less ▲]

Detailed reference viewed: 21 (4 ULg)
Full Text
Peer Reviewed
See detailLong-term fracture rates seen with continued ibandronate treatment : pooled analysis of DIVA and MOBILE long-term extension studies
Miller, PD; Recker, RR; Harris, S et al

in Osteoporosis International (2014), 25(1), 349-357

Detailed reference viewed: 51 (4 ULg)
Full Text
Peer Reviewed
See detailPrevalence of vitamin D inadequacy in European women aged over 80 years
Bruyère, Olivier ULg; Slomian, Justine ULg; Beaudart, Charlotte ULg et al

in Osteoporosis International (2014), 25(2), 196

Detailed reference viewed: 19 (5 ULg)
Full Text
Peer Reviewed
See detailWhat does multiplication of tidemarks mean in the ovine femora-tibial joint ?
Pirson, R; Matagne, A; Nisolle, JF et al

in Osteoporosis International (2014), 25(S2), 172

Detailed reference viewed: 28 (5 ULg)
Full Text
Peer Reviewed
See detailEconomic evaluation of an osteoporosis screening campaign: using FRAX as a prescreening tool
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2014), 25(2), 38-39

Detailed reference viewed: 57 (13 ULg)
Full Text
Peer Reviewed
See detailEight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension
Papapoulos, S; Lippuner, K; Roux, C et al

in Osteoporosis International (2014), 25(2), 46-47

Detailed reference viewed: 330 (2 ULg)
Full Text
Peer Reviewed
See detailBiochemical composition of cartilage with naturally occurring defects in the ovine femora-tibial joint
Matagne, A; Clegg, P; Tew, S et al

in Osteoporosis International (2014), 25(S2), 173

Detailed reference viewed: 22 (0 ULg)
Full Text
Peer Reviewed
See detailOdanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial
McClung, MR; Langdahl, B; Papapoulos, S et al

in Osteoporosis International (2014), 25(5), 573-575

Detailed reference viewed: 20 (1 ULg)
Full Text
Peer Reviewed
See detailQuality of life benefits of knee arthroplasty for osteoarthritis
NEUPREZ, Audrey ULg; François, Garance ULg; KURTH, William ULg et al

in Osteoporosis International (2014), 25(2), 40

Detailed reference viewed: 57 (9 ULg)
Full Text
Peer Reviewed
See detailFurther reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension
Ferrari, S; Adachi, JD; Lippuner, K et al

in Osteoporosis International (2014), 25(2), 56

Detailed reference viewed: 60 (3 ULg)
Full Text
Peer Reviewed
See detailCould internet use be promising in health prevention and promotion in menopausal women ? A preliminary report
Slomian, Justine ULg; Streel, Sylvie ULg; Appleboom, G et al

in Osteoporosis International (2014), 25(2), 309

Detailed reference viewed: 26 (6 ULg)